COLL Q2 2025 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$188M+29.4% YoY

Gross Profit

$108M57.7% margin

Operating Income

$35M18.7% margin

Net Income

$12M6.4% margin

EPS (Diluted)

$0.34

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

$72M

Free Cash Flow

$72M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$1.4B

Stockholders' Equity

$232M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$188M	$145M	+29.4%
Gross Profit	$108M	$91M	+19.4%
Operating Income	$35M	$47M	-26.0%
Net Income	$12M	$20M	-38.9%

Revenue Segments

Xtampza ER

$53M34%

Belbuca

$53M34%

Nucynta IR

$27M17%

Nucynta ER

$20M13%

Symproic

$4M2%